Biosimilars

Latest News

FDA Approves Aflibercept (Eylea) Biosimilars, Yesafili and Opuviz
FDA Approves Aflibercept (Eylea) Biosimilars, Yesafili and Opuviz

May 21st 2024

These aflibercept biosimilars are used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Q&A: Biosimilar Access, Pricing in the Spotlight
Q&A: Biosimilar Access, Pricing in the Spotlight

May 9th 2024

Asembia: Pharmacists Have a Role in Health Care System Sustainability
Asembia: Pharmacists Have a Role in Health Care System Sustainability

May 7th 2024

FDA Approves Second Formulation of Humira Biosimilar Cyltezo
FDA Approves Second Formulation of Humira Biosimilar Cyltezo

May 1st 2024

Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval
Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval

April 19th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.